News
SCYX
4.390
-1.35%
-0.060
SCYNEXIS adds veteran biopharma leader to board
TipRanks · 4d ago
Scynexis appoints Burke to Board of Directors
TipRanks · 4d ago
Press Release: SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
Dow Jones · 4d ago
*SCYNEXIS Appoints Steven Burke to Bd
Dow Jones · 4d ago
Weekly Report: what happened at SCYX last week (0914-0918)?
Weekly Report · 5d ago
Press Release: SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Dow Jones · 09/15 12:00
Weekly Report: what happened at SCYX last week (0907-0911)?
Weekly Report · 09/14 10:12
SCYNEXIS appoints Sanjay Subramanian as CFO
Seeking Alpha · 09/10 12:33
SCYNEXIS appoints new CFO amid leadership transition
TipRanks · 09/10 12:30
Scynexis Names Sanjay Subramanian CFO
NASDAQ · 09/10 12:17
Scynexis CFO Ivor Macleod retires, Sanjay Subramanian succeeds
TipRanks · 09/10 12:10
*Scynexis: Macleod to Remain Through Oct 9 to Support a Smooth Transition >SCYX
Dow Jones · 09/10 12:04
*Scynexis: CFO Ivor Macleod Retired Effective Sept 9 >SCYX
Dow Jones · 09/10 12:04
*Scynexis Subramanian's Appointment Effective Sept 9 >SCYX
Dow Jones · 09/10 12:03
*SCYNEXIS Appoints Sanjay Subramanian as Chief Fincl Officer >SCYX
Dow Jones · 09/10 12:02
SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9
Benzinga · 09/10 12:01
Press Release: SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Dow Jones · 09/10 12:01
Weekly Report: what happened at SCYX last week (0831-0904)?
Weekly Report · 09/07 10:06
Weekly Report: what happened at SCYX last week (0824-0828)?
Weekly Report · 08/31 10:13
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/26 17:06
More
Webull provides a variety of real-time SCYX stock news. You can receive the latest news about Scynexis through multiple platforms. This information may help you make smarter investment decisions.
About SCYX
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).